Contributions
Abstract: EP1437
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Neurobiology
Background: Posttranslational conversion of arginine to citrulline residues in myelin basic protein (MBP), one of the major compounds of myelin, appears to be increased in the brain of patients with multiple sclerosis (MS). Reliable body fluid biomarkers for MS diagnosis and treatment response monitoring are still lacking. We hypothesized that demyelination in MS leads to an increased release of citrulline from the brain.
Methods: Twenty-five patients with MS, 25 subjects with non-MS cerebral white matter disease and 25 controls without neurological disease (CwND) were included in this study. Groups were matched for age and gender. Clinical MS disability measures were recorded by means of Expanded Disability Status Scale (EDSS) scores and Multiple Sclerosis Severity Scores (MSSS). Citrulline was measured in plasma obtained from a peripheral vein in all study participants. Additional internal jugular venous samples were examined in 10 patients with MS and 10 CwND. Fifteen patients with MS underwent brain magnetic resonance imaging (MRI) to document total brain and T2 lesion volume.
Results: Mean peripheral venous plasma levels of citrulline were significantly increased in patients with MS (111.1 ± 124.1 µM), compared to patients with non-MS cerebral white matter disease (43.2 ± 39.8 µM, P = 0.002) and CwND (46.6 ± 34.9 µM, P = 0.021). No significantly elevated internal jugular/peripheral vein plasma citrulline ratios were observed in patients with MS. Peripheral venous plasma citrulline did not significantly correlate with EDSS scores, MSSS, MRI total brain or T2 lesion volume.
Discussion: Plasma citrulline appears to be elevated in patients with MS, but this seems not to be the result of an increased release from the brain. No relationships with clinical disability or radiological disease measures were observed in our study. The origin and significance of increased plasma citrulline in MS has to be further explored.
Disclosure: All authors: nothing to disclose
Abstract: EP1437
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Neurobiology
Background: Posttranslational conversion of arginine to citrulline residues in myelin basic protein (MBP), one of the major compounds of myelin, appears to be increased in the brain of patients with multiple sclerosis (MS). Reliable body fluid biomarkers for MS diagnosis and treatment response monitoring are still lacking. We hypothesized that demyelination in MS leads to an increased release of citrulline from the brain.
Methods: Twenty-five patients with MS, 25 subjects with non-MS cerebral white matter disease and 25 controls without neurological disease (CwND) were included in this study. Groups were matched for age and gender. Clinical MS disability measures were recorded by means of Expanded Disability Status Scale (EDSS) scores and Multiple Sclerosis Severity Scores (MSSS). Citrulline was measured in plasma obtained from a peripheral vein in all study participants. Additional internal jugular venous samples were examined in 10 patients with MS and 10 CwND. Fifteen patients with MS underwent brain magnetic resonance imaging (MRI) to document total brain and T2 lesion volume.
Results: Mean peripheral venous plasma levels of citrulline were significantly increased in patients with MS (111.1 ± 124.1 µM), compared to patients with non-MS cerebral white matter disease (43.2 ± 39.8 µM, P = 0.002) and CwND (46.6 ± 34.9 µM, P = 0.021). No significantly elevated internal jugular/peripheral vein plasma citrulline ratios were observed in patients with MS. Peripheral venous plasma citrulline did not significantly correlate with EDSS scores, MSSS, MRI total brain or T2 lesion volume.
Discussion: Plasma citrulline appears to be elevated in patients with MS, but this seems not to be the result of an increased release from the brain. No relationships with clinical disability or radiological disease measures were observed in our study. The origin and significance of increased plasma citrulline in MS has to be further explored.
Disclosure: All authors: nothing to disclose